MedPharm Names Christy Mocny Vice President of Quality

The contract drug developer has appointed a quality executive with more than 20 years of pharmaceutical and medical device experience.

Updated on Nov. 20, 2026 in People

MedPharm Names Christy Mocny Vice President of Quality

MedPharm, a contract drug development and manufacturing company for topical and transdermal products, has appointed Christy Mocny as vice president of quality. Mocny most recently served as director of corporate quality, global audits and compliance at Biogen.

Why it matters

The appointment places an executive with two decades of quality management experience at the head of MedPharm's quality function following its 2024 merger with Tergus Pharma. Quality oversight is central to drug development and manufacturing, where regulatory compliance and audit readiness directly affect a company's ability to serve its clients.

Mocny brings more than 20 years of experience in pharmaceutical and medical device quality management to the role. The announcement does not disclose changes to MedPharm's quality budget or headcount under her leadership.

The players

MedPharm

MedPharm is a contract drug development and manufacturing company focused on topical and transdermal products, formed in part through its 2024 merger with Tergus Pharma.

Christy Mocny

Christy Mocny is a pharmaceutical quality executive with more than 20 years of experience in drug and medical device quality management, most recently at Biogen.

The details

Mocny will lead MedPharm's Global Quality organization, overseeing quality systems, regulatory compliance, and audit and inspection readiness. She will also direct quality assurance operations supporting pharmaceutical development, analytical services, clinical trial materials, and commercial manufacturing.

Timeline

  1. 2024: MedPharm merged with Tergus Pharma.

  2. November 20, 2026: MedPharm announced Mocny's appointment as vice president of quality.

Market Landscape

The appointment follows MedPharm's 2024 merger with Tergus Pharma, which combined operations in the topical and transdermal contract manufacturing segment. Placing a senior quality leader over the merged organization signals an effort to align quality systems across the company's pharmaceutical development, analytical, and manufacturing services.

For patients and healthcare providers who rely on topical and transdermal medications, the appointment is an organizational change at a manufacturer rather than a change to any product. Any effect on the drugs themselves would depend on how the quality leadership transition is implemented over time.

The takeaway

Leadership changes in quality functions often signal how a manufacturer will manage regulatory compliance and inspection readiness after a merger. Readers tracking MedPharm or the contract drug manufacturing sector can watch for further quality-system announcements as the combined company integrates.

Further reading

Explore more executive moves in the People section of our business coverage.

Source note: This article includes information reported by Pharmabiz.